Gerry J L, Achuff S C, Becker L C, Pond M S, Greene H L
JAMA. 1979 Dec 28;242(26):2858-61.
Thirty-five patients with atypical chest pain were given ergonovine maleate as a provocative test for coronary spasm. None of the patients had significant coronary atherosclerosis. The patients were divided into two groups based on clinical information available before ergonovine testing. Group 1 patients (n=13) had objective evidence of cardiac disease manifested by episodes of syncope, ventricular tachyarrhythmias, myocardial infarction, or transient ST segment shifts with chest pain. Group 2 patients had chest pain but no objective evidence of cardiac disease. The ergonovine test was positive in 11 of 13 patients in group 1. None of the 22 group 2 patients had a positive response to ergonovine. These data suggest that ergonovine testing does not allow for any more precise recognition of patients with atypical chest pain who have coronary artery spasm than do clinical data alone.
35例非典型胸痛患者接受了马来酸麦角新碱激发试验以检测冠状动脉痉挛。所有患者均无显著冠状动脉粥样硬化。根据麦角新碱试验前可得的临床信息,将患者分为两组。第1组患者(n = 13)有心脏病的客观证据,表现为晕厥发作、室性快速心律失常、心肌梗死或胸痛伴短暂ST段移位。第2组患者有胸痛,但无心脏病的客观证据。第1组13例患者中有11例麦角新碱试验呈阳性。第2组22例患者中无一例对麦角新碱有阳性反应。这些数据表明,与仅靠临床数据相比,麦角新碱试验并不能更精确地识别出患有冠状动脉痉挛的非典型胸痛患者。